1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Sanofi/Regeneron’s Esophagitis Data Add To Dupixent’s Winning Streak

 
• By Alaric DeArment

The companies announced positive Phase III data for the drug in patients with eosinophilic esophagitis and plan to take the results to regulators in 2022.

Sanofi and Regeneron announced results from a Phase III trial of Dupixent in eosinophilic esophagitis • Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals, Inc. added to the arsenal of data supporting Dupixent (dupilumab) on 25 October with Phase III results in eosinophilic esophagitis (EoE), a disease with no approved treatments but in which the drug now emerges as a leading commercial contender. The EoE data are part of a string of wins lately for Dupixent in various inflammatory diseases.

The companies announced results from their second Phase III study in EoE, which tested Dupixent at 300mg dosed once-weekly in 159 patients aged 12 and older, showing a statistically significant improvement in the ability of patients treated with the drug to swallow and reductions of eosinophils in the esophagus relative to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

More from Therapy Areas

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.